Interpretation of RET Immunostaining in Follicular Lesions of the Thyroid
Authors:
Open Access
- 1 August 2002
- journal article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 118 (2) , 186-193
Abstract
We applied monoclonal antibodies against RET and cytokeratin 19 (CK19) to the following tumor sections: classic papillary carcinoma (PC), 16; HürthleKeywords
This publication has 20 references indexed in Scilit:
- Immunohistochemical Diagnosis of Papillary Thyroid CarcinomaLaboratory Investigation, 2001
- Oncogenes and Thyroid CancerClinical Chemistry and Laboratory Medicine (CCLM), 2000
- High Prevalence of RET/PTC Rearrangements in Ukrainian and Belarussian Post-Chernobyl Thyroid Papillary Carcinomas: A Strong Correlation between RET/PTC3 and the Solid-Follicular Variant1The Journal of Clinical Endocrinology & Metabolism, 1999
- Oncogene profile of papillary thyroid carcinomaSurgery, 1999
- Keratin subsets in papillary and follicular thyroid lesionsVirchows Archiv, 1997
- Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratinsVirchows Archiv, 1997
- Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas.Endocrinology, 1996
- Expression of the ret proto‐oncogene product in human normal and neoplastic tissues of neural crest originThe Journal of Pathology, 1994
- Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.Journal of Clinical Investigation, 1992
- PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomasCell, 1990